The protein biomarker-based test will be used to identify patients at high risk of cancer in order to prioritize them for conventional cancer screening methods.

The work will focus on addressing unmet needs in breast cancer, including the diagnosis and treatment of patients with rare cancer subtypes.

The three-year award from the National Institute for Health and Care Research will support finalization of the test as well as initial validation studies.

Last week, readers were most interested in a story about the FDA's decision not to appeal a court decision vacating the agency's LDT rule.

The test is the last of three multiplex bloodstream infection panels that the firm has designed for its Liaison Plex molecular testing instrument.

Multiple presentations at the meeting discussed the utility of circulating tumor DNA to guide treatment for colorectal cancer.

The Randox ConcizuTrace ELISA is used to determine the concentration in blood of Novo Nordisk's Alhemo (concizumab-mtci) to aid dose adjustments.

Called Velo, the system can perform true PCR testing in 10 minutes or less and is intended for use in decentralized spaces.

A new study found that women who received mail-in self-collection kits participated in screening at much higher rates than those who just received a telephone reminder.

The firm is maintaining its full-year guidance and expects to make the acquisition once Lex Diagnostics obtains 510(k) clearance of its system.

Company officials disclosed that it had been eyeing an out from Savanna in the potential acquisition of Lex Diagnostics for at least the past 18 months.

The researchers reported in Nature Communications that the PCR-based test and bedside instrument can identify the risk of sepsis within 24 hours.